Filter lifetimes of different hemodiafiltration membrane materials in dogs: reevaluation of the optimal anticoagulant dosage
Abstract Background In continuous renal replacement therapy (CRRT), administration of anticoagulants is necessary for achieving a certain level of filter lifetime. Generally, anticoagulant doses are controlled to keep activated partial thromboplastin time and other indicators within a certain target...
Main Authors: | Hiroko Yuzawa, Yousuke Hirose, Tomonori Kimura, Keisuke Shinozaki, Moe Oguchi, Tomohiro Morito, Tomohito Sadahiro |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Renal Replacement Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41100-021-00323-1 |
Similar Items
-
AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
by: Takahiro Hirayama, et al.
Published: (2017-07-01) -
Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
by: Sung Joon Han, et al.
Published: (2018-04-01) -
Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan
by: Hiroshi Kamijo, et al.
Published: (2020-08-01) -
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
by: Toru Hifumi, et al.
Published: (2020-08-01) -
The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
by: Xi Chen, et al.
Published: (2019-09-01)